About: Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 09 February 2010

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2010 (fr) наукова стаття, опублікована в лютому 2010 (uk) im Februar 2010 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 09 February 2010 (en) artículu científicu espublizáu en febreru de 2010 (ast)
publication date	wds:Q82849348-7746AE50-C5DA-4D41-BD16-5F9F82F32B59
publication date	2010-02-09 00:00:00Z (xsd:dateTime)
cites work	wds:Q82849348-14531A99-7EF3-40FD-A09C-AB6CD67E405A wds:Q82849348-16ABE0AE-577F-4827-A693-A4B6B88775F8 wds:Q82849348-185C719B-A502-4AE5-8807-D120E2A3C864 wds:Q82849348-1BC4588A-812B-4A4E-9F26-3ED10400174A wds:Q82849348-2352D4A8-C458-463B-85CC-27091C707BA1 wds:Q82849348-28290028-2562-43A4-8BF8-D314344150EB wds:Q82849348-2A0164C7-B565-4765-86B8-827B9DB9C6C4 wds:Q82849348-3BC220DA-9B2F-4663-970C-25C24620979E wds:Q82849348-3E8BAEE0-1244-4821-AD13-7048AC05573B wds:Q82849348-4B9C5AE2-4657-4BF6-AED8-304974217F5A wds:Q82849348-6A9D57C7-395D-4A0E-8243-4BDB8C417A54 wds:Q82849348-6EE31FFD-9FC8-4632-9BBD-74A750529FB9 wds:Q82849348-70545820-5369-4876-A1CB-E8DECBF3331F wds:Q82849348-71F27812-7A87-456D-8901-9F84A7F82992 wds:Q82849348-75063AE6-337F-4075-8901-DAA9577DBBBC wds:Q82849348-94EAA3E1-E8C7-4273-903F-3349C8EBB0FC wds:Q82849348-9A940B91-90D4-43B0-B4E2-DC8E24A8937A wds:Q82849348-B2794C5D-DA8E-4B35-8390-6FCBC8DD2569 wds:Q82849348-C2F37794-C7A0-4E5A-BE89-23286AFBB6C4 wds:Q82849348-C3765428-C1EF-4A42-A87A-F21B658B1C47 wds:Q82849348-C61CF7EB-87A1-439A-8168-1042F76D3D7F wds:Q82849348-C6EF0876-4F00-4A2C-92D0-A65E4C7A9E5E wds:Q82849348-D62ED999-910A-4290-8D19-4F90F03421C8 wds:Q82849348-D8B1EBAB-2268-4C30-B69D-E1ADC99B47B7 wds:Q82849348-E4672E78-3130-4CD2-ABBE-11686200D8C4 wds:Q82849348-F2EC1313-FCEE-4BCE-9BBB-F2BF5799134C wds:Q82849348-F3F21153-87B4-4E5E-BD16-96F828F127CD wds:Q82849348-F6BF5B38-D874-4FEF-854D-0508ADF270A6 wds:Q82849348-FAC4DFE8-13ED-42A8-943F-518C584885B9 wds:Q82849348-FD0177BB-D038-45EC-BAA5-613B95E0CDE3
cites work	Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Infliximab for induction and maintenance therapy for ulcerative colitis A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. Certolizumab pegol for the treatment of Crohn's disease Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial Maintenance therapy with certolizumab pegol for Crohn's disease Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis Natalizumab Induction and Maintenance Therapy for Crohn's Disease Optimizing anti-TNF treatment in inflammatory bowel disease Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease Immunogenicity of recombinant DNA human insulin Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
author name string	wds:Q82849348-6EE5DA7B-AE24-454C-AB1D-BA5F303330E5 wds:Q82849348-A30022BB-6249-41AC-9655-AA7B44C9102A wds:Q82849348-CF0CFF5D-59A9-4C74-A13B-B2AADB74F89B wds:Q82849348-D2ED2492-B372-440A-8BEA-93A470C4DD87 wds:Q82849348-D39F57FA-D633-4E1E-8180-E4BFAD56086B
author name string	Sunanda V Kane Waqqas Afif David H Bruining William A Faubion Karen A Hanson
rdfs:label	Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease (en) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease (nl)
skos:prefLabel	Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease (en) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease (nl)
name	Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease (en) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease (nl)
author	wds:Q82849348-3984698C-1158-4D06-99A9-C3DB6A7374CB wds:Q82849348-DF2FF857-6BBD-4D49-9B86-EE716AB0FF74
author	William Jeffery Sandborn Edward V Loftus
title	wds:Q82849348-3D7FDBB4-E128-4B94-A073-7BB6801AB651
title	Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease (en)
page(s)	wds:Q82849348-C061EAF7-EE89-43D1-A57B-1948885E5096
page(s)	1133-1139
instance of	wds:Q82849348-105692DA-2455-4976-8A5E-0F87065AC385
instance of	scholarly article
main subject	wds:Q82849348-63D148D8-2AAB-4785-A4F2-DB8A1FFB38E4
main subject	inflammatory bowel diseases
PubMed ID	wds:Q82849348-D66AA2A1-B077-40AC-AD81-475618E8CA1C
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20145610
PubMed ID	20145610

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software